OncLive SOSS

Authors

Latest:

Dr Lin on the Effect of Perioperative Treatment on Surgical Approaches in NSCLC

Jules Lin, MD, discusses how approaches to surgical intervention in non–small cell lung cancer may have shifted with the increasing use of targeted therapy and immunotherapies in the adjuvant and neoadjuvant setting.

Su H. Wang, MD, MPH

Latest:

Dr. Wang on the Rationale for Viral Hepatitis Screening to Prevent HCC

Su H. Wang, MD, MPH, discusses the rationale for the integration of viral hepatitis screening and care in a hospital system as the first steps for preventing liver cancers like hepatocellular carcinoma.

Jeremy C. Jones, MD

Latest:

Dr Jones on the Application of ctDNA Testing in CRC

Jeremy C. Jones, MD, discusses the applications of circulating tumor DNA testing in colorectal cancer.

Noah Stansfield

Latest:

BASECAMP-1 Trial Aims to Identify Patients With Solid Tumors Who Are Eligible for A2B530

The observational BASECAMP-1 screening study has started to identify patients with advanced solid tumors harboring somatic human leukocyte antigen-A*02 loss of heterozygosity who would be eligible to receive the novel Tmod CAR T-cell therapy, A2B530, if their cancer relapses after standard of care treatment.

John Lister, MD

Latest:

Dr. Lister on Selecting Patients With Lymphoma for CAR T-Cell Therapy

John Lister, MD, discusses selecting patients with lymphoma for CAR T-cell therapy.

Kathleen A. Dorritie, MD

Matthew Frank, MD, PhD

Latest:

Dr Frank on the Background of Investigating CAR22 Therapy in Relapsed/Refractory LBCL

Matthew Frank, MD, PhD, discusses findings from prior research investigating a CD22-directed CAR T-cell therapy that informed the rationale for launching a phase 1 trial with this agent in patients with relapsed/refractory large B-cell lymphoma.

Rinath M. Jeselsohn, MD

Latest:

Dr Jeselsohn on Enrollment Criteria For the VERITAC-2 Trial in ER+ Breast Cancer

Rinath M. Jeselsohn, MD, discusses enrollment criteria for the phase 3 VERITAC-2 trial, as well as the potential clinical implications of this research for patients with advanced estrogen receptor–positive/HER2-negative metastatic breast cancer.

Douglas Ney, MD

Latest:

Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MD

Drs Camidge and Ney discuss Dr Ney’s journey to becoming a neurologic oncologist and his experience as a physician with Tourette syndrome.

Paul L. Nguyen, MD

Latest:

Dr. Nguyen on Primary Analysis of the FORMULA-509 Trial in Prostate Cancer

Paul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.

Mark Fleury, PhD

Latest:

Dr. Fleury on the Advancement of Decentralized Clinical Trials During COVID-19

Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.

Rana R. McKay, MD, University of California, San Diego

Latest:

Dr McKay on the Rationale for Evaluating Radium-223 Plus Olaparib in mCRPC With Bone Metastases

Rana R. McKay, MD, discusses unmet needs in mCRPC that led to the inception of the COMRADE trial.

Sachdev P. Thomas, MD

Latest:

Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid Tumors

Sachdev P. Thomas, MD, discusses the utility of the immunotherapy response score when predicting clinical benefit with pembrolizumab in advanced solid tumors.

Hidehito Horinouchi, MD, PhD

Latest:

Dr Horinouchi on Safety Data for Adjuvant Alectinib in ALK+ NSCLC

Hidehito Horinouchi, MD, PhD, discusses safety data for adjuvant alectinib vs chemotherapy in ALK-positive non–small cell lung cancer.

Latest:

LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05

An expert discusses Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05

Amanda Herrmann, MD

Amanda Herrmann, MD is a third year oncology fellow at the University of California San Diego.

Latest:

Dr Herrmann on Assessing Time Toxicity in Lung Cancer Trials

Amanda Herrmann, MD, discusses findings from the TIME-TOX Lung study, which retrospectively assessed the time toxicity associated with lung cancer clinical trials.

Kristen Spencer, DO

Kristen Spencer, DO, is an associate professor in the Department of Medicine at NYU Grossman School of Medicine and director of the Phase 1 Developmental Therapeutics Program at NYU Langone Perlmutter Cancer Center in New York.

Latest:

Dr Spencer on the Rationale of Evaluating a Novel CAR T-Cell Product in Pancreatic Cancer

Kristen Spencer, DO, details the rationale of the phase 1/2 EVEREST-2 trial evaluating the novel CAR T product A2B694 in pancreatic cancer.

Karam Al-Issa, MD

Latest:

Student Loan Debt, Immigration Status Often Drive Career Decisions for Fellows

Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.

Michelle Afkhami, MD

Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College

Latest:

Ongoing Clinical Trials in the Metastatic CRPC Setting

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.